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RESEARCH ARTICLE

Construction and Radiolabeling of Adenovirus Variants
that Incorporate Human Metallothionein into Protein IX
for Analysis of Biodistribution
Lei Liu, Buck E. Rogers, Natalia Aladyshkina, Bing Cheng, Stephen J. Lokitz, David T. Curiel, and J. Michael Mathis

Abstract
Using adenovirus (Ad)-based vectors is a promising strategy for novel cancer treatments; however, current tracking approaches in
vivo are limited. The C-terminus of the Ad minor capsid protein IX (pIX) can incorporate heterologous reporters to monitor
biodistribution. We incorporated metallothionein (MT), a low-molecular-weight metal-binding protein, as a fusion to pIX. We
previously demonstrated 99mTc binding in vitro to a pIX-MT fusion on the Ad capsid. We investigated different fusions of MT within
pIX to optimize functional display. We identified a dimeric MT construct fused to pIX that showed significantly increased
radiolabeling capacity. After Ad radiolabeling, we characterized metal binding in vitro. We explored biodistribution in vivo in control
mice, mice pretreated with warfarin, mice preimmunized with wild-type Ad, and mice that received both warfarin pretreatment and
Ad preimmunization. Localization of activity to liver and bladder was seen, with activity detected in spleen, intestine, and kidneys.
Afterwards, the mice were euthanized and selected organs were dissected for further analysis. Similar to the imaging results, most of
the radioactivity was found in the liver, spleen, kidneys, and bladder, with significant differences between the groups observed in the
liver. These results demonstrate this platform application for following Ad dissemination in vivo.

Barriers to Gene Therapy Approaches for Cancer
As the limits of existing treatments for cancer are
recognized, it has become clear that novel therapies must
be considered for successful treatment; cancer therapy
using adenovirus (Ad) vectors is a promising strategy.1 The
existing approaches to Ad-based cancer therapy include
(a) mutation compensation, (b) molecular chemotherapy,
(c) genetic immunopotentiation, (d) genetic modulation
of resistance or sensitivity, and (e) oncolytic therapy or
virotherapy. Despite promising results, major limitations
have been defined in the application of serotype 5 Ads
based on clinical and preclinical studies such as a high
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prevalence of Ad-neutralizing antibodies,2 downregulation
of the coxsackie-adenovirus receptor (CAR),3 and Ad
sequestration by the liver.4 In addition, current clinical
biodistribution tracking of Ad vectors in vivo is limited to
invasive procedures such as biopsies, which are sampling
error prone, cannot be repetitively performed, and do not
give a full representation of the pharmacokinetics involved.

Current Detection Methods Are Inadequate for Ad
Vector Systems
Several imaging approaches have attempted to track Ad
biodistribution, particularly the use of reporter genes, such
as green fluorescent protein (GFP),5 somatostatin receptor
type 2 (SSTR-2),6–8 sodium iodide symporter (NIS),9,10
firefly luciferase,11,12 and herpes simplex virus thymidine
kinase (HSV-TK),13,14 as well as soluble marker peptides
such as human carcinoembryonic antigen (hCEA)15 and bhuman chorionic gonadotropin (b-hCG).16 Despite their
utility for assessing gene delivery and expression, these
reporters and markers by themselves are not suitable for
monitoring physical biodistribution. The major drawback to
approaches that tag viruses with reporter genes is that these
systems require initial viral infection and subsequent cellular
expression of a reporter gene to allow noninvasive imaging.
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Thus, detection is restricted to infected cells expressing the
reporter gene, which does not represent the physical
distribution of the virus itself. Likewise, the use of reporter
systems cannot reflect the pharmacodynamics of viral vector
particles and the kinetics of vector clearance.

Capsid Protein IX is a Potential Imaging Location
for Labeling Ads
We and other groups defined the C-terminus of protein IX
(pIX) as a locus presenting incorporated heterologous
ligands17,18 as well as for incorporating reporter genes, such
as HSV-TK,19 luciferase,20 and fluorescent proteins.21–23 To
extend this concept, we devised a novel approach to
incorporate the human metallothionein (MT) protein as a
fusion to the Ad minor capsid protein pIX.24 MT is a
ubiquitous, low-molecular-weight, metal-binding protein
that participates in heavy metal metabolism and detoxification.25 Mammalian forms of MT bind seven metal ions in
tetrahedral metal-thiolate clusters, including 99mTc,26,27 a
commonly used medical isotope useful for radioimaging by
single-photon emission computed tomography (SPECT).
Our previous study demonstrated the feasibility of 99mTc
binding in vitro to the pIX-MT fusion on the capsid of Ad
virions using a simple transchelation reaction.24 We showed
the capability for in vivo SPECT imaging of a mouse after
administration of a 99mTc-radiolabeled Ad. However, this
study was limited by low incorporation of 99mTc into the
MT construct.

Incorporating Human MT into pIX for Analysis of
Biodistribution
In our current study, we sought to investigate different
fusions of MT within pIX to optimize 99mTc radiolabeling
for functional display of this gene product. We identified a
dimeric MT construct that shows a significant increase in
99m
Tc-radiolabeling activity and characterized metal binding. Furthermore, we explored the ability to noninvasively
observe Ad biodistribution and the kinetics of uptake in
vivo on a whole-body level. These results demonstrate the
possibility of detecting Ad dissemination for monitoring
safety in vivo.

Materials and Methods
Cell Culture
The human embryonic kidney epithelial cell line (HEK293)
and the human lung adenocarcinoma epithelial cell line

(A549) were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). The cell lines were
grown in high-glucose Dulbecco’s Modified Eagle Medium
(DMEM, Invitrogen, Carlsbad, CA) containing 100 IU/mL
penicillin, 100 mg/mL streptomycin, and 2 mM L-glutamine
(Invitrogen) and supplemented with 10% fetal bovine
serum (Atlanta Biologicals, Lawrenceville, GA). The cells
were maintained at 37uC and 5% CO2 under humidified
conditions and subcultured using a 0.25% (w/v) trypsin–
0.53 mM ethylenediaminetetraacetic acid (EDTA) solution
(Invitrogen).
Animals
Female C57BL6 mice at 4 to 6 weeks of age were obtained
from Charles River Laboratories (Wilmington, MA). All
animals received humane care based on guidelines set by
the American Veterinary Association. The experimental
protocols involving live animals were reviewed and
approved by the Institutional Animal Care and Use
Committee of LSU Health Sciences Center in Shreveport.
Recombinant Ad Construction
An initial pIX-MT intermediate sequence in pUC57 was
constructed by synthesizing a 932 bp DNA fragment
(GenScript, Piscataway, NJ) corresponding to amino acids
106 to 140 of the Ad serotype 5 pIX protein-coding
sequence, followed by a 15–amino acid linker (GGGGSGGGGSGGGGS), amino acids 1 to 61 of the human
MT 1A sequence, a 16 bp DNA linker sequence (TGAGCTAGCGACGTCA), and the 583 bp DNA sequence
immediately upstream of the pIX gene (bp 4032–4614,
GenBank accession AY339865). Additional DNA fragments were synthesized containing spacer sequences consisting of a 30 Å spacer of 25 amino acids corresponding to
an alpha helical linker18; a 45 Å spacer of 38 amino acids
from ApoE4 cDNA (bp 373–472, GenBank accession
XM_008844); an ABD spacer of 46 amino acids from the
albumin-binding domain 3 (ABD) of streptococcal protein G (bp 880–925, Genbank accession X06173); a 75 Å
spacer of 63–amino acid fusion consisting of the 30 Å and
45 Å spacers; and a red fluorescent protein (RFP) spacer
equivalent to 238 amino acids from the monomeric RFP
gene (bp 1–711, Genbank accession AY678264.1). These
synthetic DNA fragments were subcloned directly into the
MfeI - BstXI sites of the AdenoVatorCMV5 shuttle vector
(QBiogene, Carlsbad, CA). A turboGFP (tGFP) complementary DNA sequence (Axxora, San Diego, CA) was also
subcloned into the CMV5 expression polylinker site of
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pAdenoVatorCMV5 for use as a reporter gene, and the
CMV5 promoter was replaced with the human survivin
promoter gene sequence from 2230 to +30 bp. The
resulting pAdenoVator-Survivin-tGFP-pIX-MT shuttle
vectors were used to construct recombinant Ad plasmids
by homologous recombination with pAdEasy1 (containing
the E1 and E3 deleted Ad5 backbone) in Escherichia coli
using methods previously described.28 The resultant
recombinant plasmids were linearized with Pac I and
transfected into HEK293 cells to generate and rescue Ad
virions. The wild-type Ad and Ad-tGFP-pIX-MT vectors
used as controls have been described previously.24
Virus Propagation and Purification
Viruses were propagated in HEK293 cells, which do not express
wild-type pIX. Viruses were purified by double CsCl ultracentrifugation and dialyzed against Dulbecco’s phosphatebuffered saline (PBS) containing 10% glycerol. Final aliquots
of virus were analyzed for viral particle (vp) titer using
absorbance at 260 nm and a conversion factor of 1.1 3 1012.
Multiplicity of infection (MOI) was determined using an
Adeno-X Rapid Titer Kit (Clontech, Mountain View, CA)
and represents the number of infectious units (ifu) of virus.
Viruses were stored at 280uC until use.
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Fisher Scientific, Rockford, IL), followed by a secondary
horseradish peroxidase (HRP)-conjugated goat antirabbit
mouse IgG antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) or HRP-conjugated goat antimouse IgG antibody (Santa
Cruz Biotechnology). Specific protein bands were detected by
chemiluminescence using Amersham ECL Plus reagents (GE
Healthcare, Piscataway, NJ).
Radiolabeling of Virus and Gel Chromatography
For radiolabeling Ad virions, 10 to 40 mCi of 99mTcpertechnetate in 0.5 mL saline was reduced in the presence
of glucoheptonate30 using a modified kit (10 mg sodium
glucoheptonate and 25 mg SnCl2) for 15 minutes at room
temperature. The 99mTc-glucoheptonate (225 mL) was then
added directly to aliquots of Ad (0.1–10 3 1011 vp in 75 mL
containing 3.3 mg/mL bovine serum albumin). Incubation
with Ad aliquots proceeded for 15 to 120 minutes at 37uC.
Purification of radiolabeled Ad virions from free 99mTc
and 99mTc-glucoheptonate was performed by size-exclusion
chromatography using Sephacryl S-100 HR (GE Healthcare).
Viral particle titer of each fraction was determined by
measuring the absorbance at 260 nm in a spectrophotometer,
using a conversion factor of 1.1 3 1012 vp per absorbance
unit.31 The radioactivity of each fraction was measured with a
CRC-25R dose calibrator (Capintec, Ramsey, NJ).

Ad Replication Assay
The HEK293 cell line was infected with each Ad construct
at 10:1 MOI. The infected cells were incubated for up to
4 days at 37uC. After each time point, replicate cells were
collected and resuspended in 0.2 mL PBS. Total genomic
DNA was extracted using a Qiagen DNA-mini kit
(Valencia, CA), and Ad E4 copy number was determined
by quantitative polymerase chain reaction (PCR). For this
assay, the following sets of primers and probes were
designed and used: sense (59-GGGTCGCCACTTAATCTACCT-39), antisense (59-GCAAGGCGCTGTATCCAA-39),
and probe (59FAM-CGCTTGTGGTATGATGGCCACGTTAMRA-39).
Western Blot Analysis
Purified Ad virions were lysed in RIPA buffer, resolved
on precast 4 to 20% gradient sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) gels (Thermo
Scientific Pierce, Rockford, IL), and transferred to nitrocellulose membranes. Staining was performed using a rabbit
antiadenovirus pIX polyclonal antibody29 or a monoclonal
anti-Ad hexon monoclonal antibody (clone 65H6, Thermo

Metal Competition Assay
Aliquots of the radiolabeled Ads were incubated in the
absence or presence of nonradioactive competitor metal
ions. After addition of competitor metal using 1003 stock
solutions, the aliquots were incubated at room temperature
or at 37uC for 15 minutes. The Ad-bound and free 99mTc
were separated using P-30 micro spin columns (Bio-Rad,
Hercules, CA) and quantified using a dose calibrator
(Capintec).
SPECT/CT Scanning of Ad-Infected Mice
Groups of mice were preimmunized with wild-type Ad by
intraperitoneal injection with 1 3 1010 vp at 3 weeks and
1 week prior to SPECT imaging. To deplete vitamin K–
dependent coagulation factors, groups of mice were
injected subcutaneously with 133 mg of warfarin in
100 mL of peanut oil at 3 and 1 days prior to SPECT
imaging. Mice were initially injected via the tail vein with
approximately 750 mCi of the radiolabeled Ad, and image
acquisition was started at 60 minutes afterwards. The
animals were anesthetized using isoflurane and fixed in a
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prone position on the bed and center of rotation relative
to the gantry of a dedicated small-animal trimodality
positron emission tomography (PET)/SPECT/computed
tomography (CT) system (TriFoil Imaging, Northridge,
CA). Three-dimensional (3D) SPECT imaging was performed in a step-and-shoot manner using the following
acquisition parameters: 64 projections, 30 seconds/projection (35-minute image acquisition), with a 140 keV
photopeak 6 10% window. SPECT 3D reconstructions
were performed using an ordered subset expectation
maximization (OSEM) iterative reconstruction algorithm
with five iterations of four subsets (TriFoil Imaging).
Immediately after each SPECT imaging was performed, a
CT image was acquired using the same coordinates with
256 projections and 1024 3 1024 projection matrix size
and a voltage of 60 kV; CT reconstructions were
performed using filtered backprojections. The SPECT
and CT images were visualized and fused using Amira
3D analysis software (FEI Visualization Sciences Group,
Burlington, MA).
Ex Vivo Analysis
At the completion of imaging, each mouse was euthanized
with a lethal dose of isoflurane followed by cervical
dislocation. Tissues and organs, including liver, spleen,
stomach, kidneys, heart, lungs, pancreas, small intestine,
large intestine, peritoneal fat pad, bladder, and ovaries and
uterus, and blood were removed and weighed, and the
radioactivity was measured using a NaI (Tl) well counter
and MAESTRO multichannel analyzer software (Advanced
Measurement Technology, Oak Ridge, TN). Tissue and
organ uptake was calculated as percentage of injected dose
per gram of tissue (%ID/g), corrected for decay.
Statistical Analysis
All data are expressed as means 6 SEM. The in vitro
experiments were performed in triplicate. Statistical
analysis was carried out with the Student t-test using
GraphPad Prism version 5.0 software (GraphPad, La Jolla,
CA). Statistical significance was set at p , .05.

Results
Constructing Ad Vectors Containing pIX-MT Fusions
As shown in Figure 1, our initial pIX-MT fusion was
separated by a 15–amino acid flexible linker (GGGGS)33. In
this study, we hypothesized that by increasing the distance

Figure 1. Construction of adenoviruses containing pIX-MT variants.
A, Schematic representation of pIX localization within the Ad5 capsid.
B, Schematic representation of pIX-MT variants.

between the MT and the pIX C-terminus using peptide
linkers, a better display and accessibility of each individual
MT moiety of the pIX C-terminus tetramer cluster would be
obtained for radiolabeling. To test whether insertions of
alpha-helical spacers between the pIX C-terminus and the
MT sequence could improve radiometal binding, we made
fusion constructs with additional spacers of varied lengths
joining the pIX C-terminus to MT (see Figure 1B). These
constructs included three alpha-helical spacers of 26 amino
acids (30 Å), 33 amino acids (45 Å), and 78 amino acids (75
Å), as previously described.18 A spacer corresponding to the
ABD from streptococcal protein G (46 amino acids) was also
included.32 Finally, a longer spacer consisting of 251 amino
acids encoding RFP was included. Additional pIX fusions
were made using an alternative isoform of MT, MT3, as well
as an MT1A-MT1B dimer for comparison with MT1A.
We used the E. coli recombination system28 to generate
recombinant replication–deficient Ads containing an E1A
expression cassette with tGFP sequence under control of
the human survivin promoter.33 After construction, the
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propagated Ad viruses were purified by double CsCl
ultracentrifugation. After purification, the recombinant
pIX-MT fusion proteins were examined by Western blot
analysis and were clearly detected using an anti-MT
antibody (Figure 2A). These results indicate correct
introduction of the pIX-MT protein constructs into the
viral capsid and demonstrate that the spacer sequences do
not impair the incorporation of pIX into Ad capsids. For
the Ad construct containing a pIX-RFP-MT fusion (Ad5pIX-RFP-MT), two bands were identified. These likely
represent an intact pIX-RFP-MT fusion protein and a pIX
cleavage product due to an Ad protease cleavage site within
the RFP sequence.34 As a control, all Ad constructs showed
equivalent 130 kDa bands by Western blot analysis using
an anti-Ad hexon protein (Figure 2B).
Analysis of Viral DNA Replication
To investigate the replication efficacy of the spacermodified pIX-MT fusion constructs, we compared the Ad
progeny production in HEK293 cells after initial infection
(Figure 3). As a control, virus production was compared to
a wild-type Ad. In this experiment, 10 ifu/cell of the
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Figure 3. Replication of pIX-MT variants in HEK-293 cells. Viral
copy number was used as an indicator of viral replication in HEK293
cells. Growth medium was collected at 1, 2, 3, and 4 days after
infection with Ad constructs at an MOI of 10 ifu/cell. Each point
represents the mean 6 SE of three replicate samples.

different Ads were used to infect the human embryonic
kidney epithelial (HEK293) cell line. Aliquots of medium
were collected on 1, 2, 3, and 4 days postinfection, and total
DNA was extracted from the medium and analyzed for Ad5
viral E4 DNA copy number by quantitative PCR. Medium
from uninfected cells was also obtained at each time point to
serve as a baseline for viral replication. From days 1 through
3 postinfection, the E4 copy number for each of the Ad
constructs increased logarithmically. Afterwards, from day 3
to day 4 postinfection, the E4 copy number for each of the
Ad constructs reached a plateau. Taken together, these data
indicate that the Ad constructs with modified pIX genes
show similar replication patterns in HEK293 cells, and this
replication is comparable to an Ad construct with a wildtype pIX gene.
Analysis of Viral Infectivity

Figure 2. Determination of pIX-MT incorporation. Aliquots of the
purified viruses were separated by SDS-PAGE, electroblotted onto
nitrocellulose, and probed with (A) an anti-pIX antibody or (B) an
antihexon antibody, followed by treatment with corresponding
antispecies IgG HRP conjugates. Shown are representative blots after
visualization by autoradiography.

To assay the infection efficacy of the spacer-modified pIXMT fusion constructs, the A549 cell line was used, which is
highly permissive to Ad infection due to expression of the
Ad receptor CAR but is nonpermissive for replication of
E1A-deleted Ads. In this experiment, 2 3 105 cells were
plated into 24-well tissue culture dishes and infected for
2 hours with increasing MOI of the spacer-modified pIXMT fusion constructs from 0.1 to 100 ifu/cell. At 48 hours
after infection, the percentage of infected cells was
determined by quantifying GFP expression using flow
cytometry analysis. All the Ad vectors had an identical
backbone, the difference being the incorporation of these
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alternative spacer modifications in the pIX-MT. The
results shown in Figure 4 indicate that the pIX-MT spacer
modifications did not affect the efficiency in infecting
A549 cells in vitro.
Radiolabeling of Ad Vectors with

99m

Tc

We initially compared the radiolabeling efficiency of 99mTc
binding in vitro using the spacer-modified pIX-MT fusion
constructs. In this experiment, 99mTc-pertechnetate was
reduced in the presence of SnCl2 and weakly chelated to
glucoheptonate for 15 minutes at room temperature.
Afterwards, the 99mTc-glucoheptonate was added directly
to the Ad samples for transchelation reactions. Incubation
with each Ad sample proceeded up to 120 minutes at 37uC.
Purification of 99mTc-radiolabeled Ads from 99mTc-glucoheptonate was performed by size-exclusion chromatography using 10 mL Sephacryl S-100 columns. Collection of
0.35 mL fractions proceeded until activity peaks corresponding to Ad virions were obtained in the void volume. The
fractions with the highest radioactivity between 6 and 9 also
corresponded to the highest Ad particle number and
infectious activity (data not shown). As shown in Figure 5,
the peaks for each of the Ads containing spacer-modified
pIX-MT fusion constructs showed similar radioactivity
bound compared to an Ad construct lacking any spacer
sequence. As a control, we also examined radiolabeling of a
wild-type Ad construct containing an unmodified pIX; this
virus showed that little 99mTc radioactivity was incorporated.

Figure 4. Infectivity of pIX-MT variants in A549 cells. Flow
cytometric analysis of Ad-pIX-MT variants expressing green fluorescent protein marker. An analysis was performed for expression of
GFP at 48 hours after infection with increasing doses from 0.1 ifu/cell
to 1,000 ifu/cell. Values represent the mean 6 SEM of three replicate
measurements.

Figure 5. Radiolabeling of pIX-MT spacer variants with 99mTc. A,
Schematic representation of the pIX-MT variants analyzed. B, After
transchelation of the Ad variants containing pIX-MT fusions or an Ad5
vector containing a wild-type pIX with 99mTc glucoheptonate, the
radiolabeled virions were purified from unincorporated 99mTc by gel
filtration using Sephacryl S-100 columns. Each point represents the
specific activity of fractions collected in microcuries.

These results demonstrate that spacer length has little or no
significant effect on 99mTc binding in vitro to the pIX-MT
fusion on the capsid of Ad virions.
Distinct isoforms of human MT have been identified
arising from four genes that are expressed broadly in most
tissues or display tissue-specific expression patterns.35,36
The relative affinity and stability constants of metal ions
differ for recombinant MT isotypes,37 as does their stability
in various in vitro production systems.38 Therefore, we
sought to compare the 99mTc-binding capacity of pIX-MT
fusion constructs containing MT1A, MT3, or an MT1AMT1B dimer. As shown in Figure 6, the peaks for an Ad
construct containing a pIX-MT3 fusion showed similar
radioactivity bound compared to an Ad construct containing a pIX-MT1A fusion. Interestingly, we also compared
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Figure 6. Radiolabeling of pIX-MT isotype variants with 99mTc. A,
Schematic representation of the pIX-MT variants analyzed. B, After
transchelation of the Ad variants containing pIX-MT fusions with
99m
Tc glucoheptonate, the virions were purified from unincorporated
99m
Tc by gel filtration using Sephacryl S-100 columns. Each point
represents the specific activity of fractions collected in microcuries.

radiolabeling of an Ad construct containing a pIX-MT1AMT1A MT dimer fusion; this virus showed roughly twice
the 99mTc radioactivity incorporated compared to an Ad
construct containing a pIX-MT1A fusion. Quantification of
specific activity showed incorporation of approximately
0.14 mBq/vp (data not shown). Based on these results, we
continued with more extensive characterization of the pIXMT dimer fusion.
Metal Competition Assay
To determine the specificity of 99mTc binding for the pIXMT dimer fusion, we performed a metal competition assay
using increasing concentrations of CdCl2, CoCl2, CuCl2, or
ZnCl2. As shown in Figure 7, the bound radioactivity was
competed with increasing concentrations of metal, with
half-maximal concentrations required for displacement of
99m
Tc. Interestingly, these results showed similar ability of
2+
Co , Cu2+, Cd2+, and Zn2+ to displace 99mTc. Likewise,
relatively high metal concentrations were required for
displacement at room temperature, although this requirement was reduced when the radiolabeled virus was

Figure 7. Metal competition assay of a 99mTc-radiolabeled Ad.
Aliquots of 99mTc-radiolabeled Ad-pIX-MT dimer were incubated
for 15 minutes at (A) 20uC or (B) 37uC with the indicated
concentrations of CdCl2, CoCl2, CuCl2, or ZnCl2. Virus-bound
99m
Tc was determined counting radioactivity after purification
through a spin column. Each point represents the percentage of
radioactivity of a no-metal control.

coincubated at 37uC. This result contrasts to the in vitro
binding affinities to MT determined to be Cu2+ . Cd2+ .
Zn2+ . Co2+,39 possibly as a structural consequence of MT
dimerization.
Analysis of Ad Biodistribution In Vivo
After radiolabeling the Ad containing a pIX-MT dimer
fusion, we determined whether SPECT imaging could be
used to monitor Ad biodistribution and uptake in vivo. In
the experiment shown in Figure 8 and Figure 9, a group of
four control female C57BL6 mice were injected intravenously with 99mTc-radiolabeled Ad. A second group of
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Figure 9. In vivo biodistribution of a 99mTc-radiolabeled Ad. Shown
are the values obtained for the %ID/g of tissues from a group of four
untreated female C57BL6 mice injected intravenously with approximately 1 mCi of 99mTc-radiolabeled Ad-pIX-MT dimer. These values
were compared to a group of mice pretreated with warfarin, a group
of mice preimmunized with wild-type Ad, or a group of mice that
received warfarin pretreatment and wild-type Ad preimmunization.
Each bar represents the mean 6 SEM of tissues from four mice.

Figure 8. Coronal and sagittal views of fused pinhole SPECT and
micro-CT images of a mouse injected with a 99mTc-radiolabeled Ad. A,
Radiolabeling of the Ad-pIX-MT dimer by transchelation with 99mTc;
shown is a purification from unincorporated 99mTc by gel filtration
using Sephacryl S-100 columns. Each point represents the specific
activity of fractions collected in microcuries. B, A representative
C57BL6 mouse was injected intravenously with approximately 1 mCi
of 99mTc-radiolabeled Ad-pIX-MT dimer in 0.2 mL PBS and scanned
at 60 minutes after the injection. Three-dimensional rendering of fused
CT and SPECT images of bony structures in white and radiolabeled
adenovirus in red-yellow scale showing coronal (front) and sagittal
(side) views.

mice was pretreated with the drug warfarin (an inhibitor of
vitamin K–dependent coagulation factor production). This
treatment should decrease coagulation factor–mediated
liver transduction.40 A third group of mice was preimmunized with wild-type Ad, a treatment that should enhance
FcR-dependent uptake and phagocytosis by resident
Kupffer cell populations in the liver and macrophages in
the spleen.41,42 A fourth group of mice received both
warfarin pretreatment and Ad preimmunization. One
hour after 99mTc-radiolabeled Ad administration, the mice
were imaged. As shown in Figure 8, clear localization of

activity to the liver and bladder was seen, with activity also
detected in the spleen, intestine, and kidneys.
Immediately following the SPECT/CT imaging, the
animals were euthanized and selected organs were dissected
for further analyses. Radioactivity of the tissue samples was
measured using a well counter and expressed as %ID/g
tissue weight. The in vivo biodistribution results of the
dissection analysis are summarized in Figure 9, with mean
and standard error values provided in Table 1. Similar to the
results observed in the SPECT images (see Figure 8), most of
the radioactivity was found in all treatment groups in the
liver, spleen, kidneys, and bladder. However, significant
differences between the treatment groups were observed,
primarily in the liver. Liver uptake of 99mTc in control
(untreated) mice was significantly reduced by warfarin
treatment from 33.4 %ID/g to 19.7 %ID/g (p , .05).
Likewise, preimmunization with wild-type Ad resulted in a
significant increase in liver uptake of 99mTc to 52.2 %ID/g
compared to control (untreated) mice (p , .001). Finally,
liver uptake of 99mTc in preimmunized mice was significantly reduced by warfarin treatment from 52.2 %ID/g to
30.5 %ID/g (p , .001).

Discussion
We have shown herein that our novel labeling strategy for Ads
yields virions capable of incorporating functional pIX-MT
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Table 1. Biodistribution of

99m

Tc-Radiolabeled Adenovirus Based on Dissection at 1.5 Hours after Injection
Treatment

Tissue (%ID/g)
Liver
Spleen
Stomach
Kidneys
Heart
Lungs
Pancreas
Small intestine
Large intestine
Fat pad
Bladder
Ovaries/uterus
Serum

Untreated
33.4
19.9
4.54
7.89
0.302
0.871
0.644
1.93
0.323
0.575
17.5
0.434
1.12

6
6
6
6
6
6
6
6
6
6
6
6
6

4.4
6.4
2.88
1.28
0.198
0.200
0.410
0.53
0.113
0.262
15.1
0.066
0.19

Warfarin
19.7
8.10
3.11
5.66
0.401
0.450
0.217
1.36
0.375
0.109
17.1
0.679
0.952

6
6
6
6
6
6
6
6
6
6
6
6
6

fusion proteins for 99mTc radiolabeling in the context of in
vivo biodistribution studies. These results confirm the
utility of using pIX as a platform for presenting heterologous proteins on the surface of the Ad capsid for multiple
functional effects. The adenovirus pIX protein plays multiple roles, including structural virion stability as well as gene
transcriptional activation and nuclear reorganization.43 The
pIX protein resides as homotrimers within the virion capsid
and interacts as a connecting network of four trimers
to stabilize hexon proteins.44 Although the N-terminal
domains of three pIX proteins form a triskelion structure
that cements three hexons together, the C-terminal domains
form a tetramer, with three domains from one icosahedral
facet associating together in a parallel structure and a fourth
domain from an adjacent icosahedral facet associating in an
antiparallel orientation. Despite this multifunctional role in
Ad capsid structure and function, all the MT variants fused
to pIX were successfully incorporated into the Ad vector
capsid.
In this study, imaging analysis and radioactivity
determination showed localization of radioactivity primarily in the liver. On intravenous administration, Ad5based vectors are sequestered in the liver, where resident
Kupffer cells rapidly remove most of the injected dose
from circulation.45 This process depends on multiple and
synergistic interactions involving different blood components, including circulating cells, blood coagulation
factors, antibodies, and complement.34 In particular,
coagulation factor X (FX) binds to the Ad5 capsid protein
hexon at hypervariable regions (HVR) 5 and 746 and
mediates the majority of the Ad5 liver tropism, primarily
through heparin sulfate proteoglycan–mediated pathways.

Preimmunized

8.5
4.86
1.63
1.53
0.125
0.129
0.033
0.290
0.391
0.025
16.3
0.499
0.279

52.2
14.9
1.16
5.78
0.466
0.906
0.431
1.77
0.763
0.187
32.6
0.455
1.27

6
6
6
6
6
6
6
6
6
6
6
6
6

7.1
2.6
0.62
0.432
0.041
0.093
0.113
0.27
0.439
0.019
27.3
0.115
0.11

Preimmunized + Warfarin
30.5
13.5
1.27
5.91
0.408
0.508
0.229
1.67
0.479
0.179
23.5
0.272
1.03

6
6
6
6
6
6
6
6
6
6
6
6
6

2.9
2.3
0.82
1.28
0.111
0.129
0.114
0.69
0.131
0.062
17.3
0.071
0.63

Imaging analysis and radioactivity determination
showed that pretreatment with warfarin decreased liver
uptake of the 99mTc-radiolabeled Ad vector. Warfarin
pretreatment can deplete circulating FX levels and decrease
the liver tropism of intravenously administered Ad5.47 In
addition, we showed that preimmunization with Ad vector
increased subsequent liver uptake of the 99mTc-radiolabeled Ad. Beyond the role of FX, Ad inactivation and liver
clearance are also mediated through anti-Ad antibody
interactions, resulting in activation of the classic complement pathway. In the presence of anti-Ad antibodies,
classic pathway activation occurs through direct binding of
complement protein C1q to the Ad-antibody complex.48
This pathway uses the complement component 3 (C3)
protein, which has been shown to enhance liver transduction by Ads and augment the inflammatory cytokine
response. In addition, the alternative complement pathway
is activated by direct binding of complement protein C3 to
Ads,49 resulting in liver transduction despite a lack of
complement activity.
Based on x-ray crystallography and mutation studies of
the hexon HVR 5 and 7 regions, it has been possible to
identify specific amino acid residues that interact with FX
and to ablate this interaction.50 In addition, serotype
substitution of hexon has been demonstrated to decrease
binding to FX and decrease cell transduction via FXmediated pathways in vitro as well as decrease liver
sequestration in vivo.51 However, HVR mutations can also
increase spleen uptake,52 which is mediated through an
RGD motif on Ad5 penton base with integrins. Ablation of
the penton RGD motif in the context of an FX binding–
ablated Ad5 vector can decrease spleen uptake as well as
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innate inflammatory response.52 In addition to ablating
liver uptake, improving Ad tumor targeting is also
dependent on selective target infection. Ad5 infection is
mediated through the Ad fiber protein, which binds to the
primary CAR. We and others have shown that fiber knob
modifications are effective examples of different retargeting strategies to improve tumor cell infection for a variety
of cancer types and to improve antitumor efficacy of Ad5based vectors.53
Improvement of Ad5-based vectors to untarget liver
uptake and retarget tumor infectivity is critically dependent
on knowledge of biodistribution in vivo. This study
demonstrates our ability to use an Ad vector, which
encompasses MT for biodistribution analysis by 99mTcbased SPECT imaging. Besides SPECT imaging using 99mTc,
PET imaging using 94mTc54 could also be applied in the
context of Ads containing the pIX-MT fusion protein.
Likewise, 64Cu could be used for PET imaging because Cu is
bound by MT with high affinity.39 PET imaging does have
some advantages over SPECT imaging due to higher spatial
resolution and sensitivity and is easier to quantify than
SPECT imaging. Nonetheless, SPECT radiotracers are
cheaper and more widely available, without the need for
an adjacent cyclotron for production of short-lived PET
radiotracers. MT has also been demonstrated to bind
isotopes of rhenium55 (ie, 188Re or 186Re), which are capable
of combined SPECT imaging and radionuclide therapy.56,57
The ability to view real-time molecular events in vivo in
their physiologic milieu represents a significant tool to
study Ad vector biology and the consequence of different
vector modifications. Ultimately, the highest yield of
valuable information about Ad biodistribution will come
from preclinical studies and application of modified Ad
vectors in patients.

Acknowledgments
Financial disclosure of authors: This work was supported, in
part, by National Institutes of Health grant 5R01-CA154697
and funding from the Louisiana Gene Therapy Research
Consortium and the Feist-Weiller Cancer Center.
Financial disclosure of reviewers: None reported.

References
1. Wold WS, Toth K. Adenovirus vectors for gene therapy,
vaccination and cancer gene therapy. Curr Gene Ther 2013;13:
421–33, doi:10.2174/1566523213666131125095046.
2. Yu B, Dong J, Wang C, et al. Characteristics of neutralizing
antibodies to adenovirus capsid proteins in human and animal
sera. Virology 2013;437:118–23, doi:10.1016/j.virol.2012.12.014.

3. Arnberg N. Adenovirus receptors: implications for targeting of
viral vectors. Trends Pharmacol Sci 2012;33:442–8, doi:10.1016/
j.tips.2012.04.005.
4. Alba R, Bradshaw AC, Mestre-Frances N, et al. Coagulation factor
X mediates adenovirus type 5 liver gene transfer in non-human
primates (Microcebus murinus). Gene Ther 2012;19:109–13,
doi:10.1038/gt.2011.87.
5. Chen R, Parry JJ, Akers WJ, et al. Multimodality imaging of gene
transfer with a receptor-based reporter gene. J Nucl Med 2010;51:
1456–63, doi:10.2967/jnumed.109.063586.
6. Singh SP, Yang D, Ravoori M, et al. In vivo functional and
anatomic imaging for assessment of in vivo gene transfer.
Radiology 2009;252:763–71, doi:10.1148/radiol.2531081825.
7. Rogers BE, Parry JJ, Andrews R, et al. MicroPET imaging of gene
transfer with a somatostatin receptor-based reporter gene and
(94m)Tc-Demotate 1. J Nucl Med 2005;46:1889–97.
8. Kim KH, Dmitriev I, O’Malley JP, et al. A phase I clinical trial of
Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer
Res 2012;18:3440–51, doi:10.1158/1078-0432.CCR-11-2852.
9. Merron A, Baril P, Martin-Duque P, et al. Assessment of the Na/I
symporter as a reporter gene to visualize oncolytic adenovirus
propagation in peritoneal tumours. Eur J Nucl Med Mol Imaging
2010;37:1377–85, doi:10.1007/s00259-009-1379-3.
10. Barton KN, Stricker H, Brown SL, et al. Phase I study of
noninvasive imaging of adenovirus-mediated gene expression in
the human prostate. Mol Ther 2008;16:1761–9, doi:10.1038/mt.
2008.172.
11. Davydova J, Gavrikova T, Brown EJ, et al. In vivo bioimaging
tracks conditionally replicative adenoviral replication and provides
an early indication of viral antitumor efficacy. Cancer Sci 2010;101:
474–81, doi:10.1111/j.1349-7006.2009.01407.x.
12. Kim YI, Ahn BC, Ronald JA, et al. Intratumoral versus intravenous
gene therapy using a transcriptionally targeted viral vector in an
orthotopic hepatocellular carcinoma rat model. J Vasc Interv
Radiol 2012;23:704–11, doi:10.1016/j.jvir.2012.01.053.
13. Abate-Daga D, Andreu N, Camacho-Sanchez J, et al. Oncolytic
adenoviruses armed with thymidine kinase can be traced by PET
imaging and show potent antitumoural effects by ganciclovir dosing.
PLoS One 2011;6:e26142, doi:10.1371/journal.pone.0026142.
14. Pouliot F, Karanikolas BD, Johnson M, et al. In vivo imaging of
intraprostatic-specific gene transcription by PET. J Nucl Med 2011;
52:784–91, doi:10.2967/jnumed.110.084582.
15. Kanerva A, Zinn KR, Peng KW, et al. Noninvasive dual modality in
vivo monitoring of the persistence and potency of a tumor targeted
conditionally replicating adenovirus. Gene Ther 2005;12:87–94,
doi:10.1038/sj.gt.3302387.
16. Zoltick PW, Wilson JM. A quantitative nonimmunogenic
transgene product for evaluating vectors in nonhuman primates.
Mol Ther 2000;2:657–9, doi:10.1006/mthe.2000.0204.
17. Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of
adenovirus vectors containing heterologous peptide sequences in
the C terminus of capsid protein IX. J Virol 2002;76:6893–9,
doi:10.1128/JVI.76.14.6893-6899.2002.
18. Vellinga J, Rabelink MJ, Cramer SJ, et al. Spacers increase the
accessibility of peptide ligands linked to the carboxyl terminus of
adenovirus minor capsid protein IX. J Virol 2004;78:3470–9,
doi:10.1128/JVI.78.7.3470-3479.2004.

Adenovirus Variants Incorporating pIX-Metallothionein Constructs

19. Li J, Le L, Sibley DA, et al. Genetic incorporation of HSV-1
thymidine kinase into the adenovirus protein IX for functional
display on the virion. Virology 2005;338:247–58, doi:10.1016/
j.virol.2005.04.005.
20. Matthews QL, Sibley DA, Wu H, et al. Genetic incorporation of a
herpes simplex virus type 1 thymidine kinase and firefly luciferase
fusion into the adenovirus protein IX for functional display on the
virion. Mol Imaging 2006;5:510–9.
21. Ugai H, Wang M, Le LP, et al. In vitro dynamic visualization
analysis of fluorescently labeled minor capsid protein IX and core
protein V by simultaneous detection. J Mol Biol 2010;395:55–78,
doi:10.1016/j.jmb.2009.10.034.
22. Le LP, Li J, Ternovoi VV, et al. Fluorescently tagged canine
adenovirus via modification with protein IX-enhanced green
fluorescent protein. J Gen Virol 2005;86:3201–8, doi:10.1099/
vir.0.80968-0.
23. Le LP, Everts M, Dmitriev IP, et al. Fluorescently labeled
adenovirus with pIX-EGFP for vector detection. Mol Imaging
2004;3:105–16, doi:10.1162/1535350041464874.
24. Mathis JM, Bhatia S, Khandelwal A, et al. Genetic incorporation of
human metallothionein into the adenovirus protein IX for noninvasive SPECT imaging. PLoS One 2011;6:e16792, doi:10.1371/
journal.pone.0016792.
25. Babula P, Masarik M, Adam V, et al. Mammalian metallothioneins: properties and functions. Metallomics 2012;4:739–50, doi:
10.1039/c2mt20081c.
26. Burchiel SW, Hadjian RA, Hladik WB, et al. Pharmacokinetic
evaluation of technetium-99-metallothionein-conjugated mouse
monoclonal antibody B72.3 in rhesus monkeys. J Nucl Med 1989;
30:1351–7.
27. Morelock MM, Tolman GL. Metallothionein: a bifunctional
chelator for the radiolabeling of biologically active molecules.
Experientia Suppl 1987;52:247–53, doi:10.1007/978-3-0348-67849_19.
28. He TC, Zhou S, da Costa LT, et al. A simplified system for
generating recombinant adenoviruses. Proc Natl Acad Sci U S A
1998;95:2509–14, doi:10.1073/pnas.95.5.2509.
29. Manser E, Loo TH, Koh CG, et al. PAK kinases are directly coupled
to the PIX family of nucleotide exchange factors. Mol Cell 1998;1:
183–92, doi:10.1016/S1097-2765(00)80019-2.
30. Agha NH, Al-Hilli M, Karim HM, et al. Instant 99mTc-labelled
glucoheptonate kit for kidney imaging. Nuklearmedizin 1983;22:
246–50.
31. Maizel JV Jr, White DO, Scharff MD. The polypeptides of
adenovirus. I. Evidence for multiple protein components in the
virion and a comparison of types 2, 7A, and 12. Virology 1968;36:
115–25, doi:10.1016/0042-6822(68)90121-9.
32. Hedley SJ, Krendelshchikov A, Kim M-H, et al. Assessment of
genetic shielding for adenovirus vectors. Open Gene Ther J 2009;2:
1–11, doi:10.2174/1875037000902010001.
33. Van Houdt WJ, Haviv YS, Lu B, et al. The human survivin promoter:
a novel transcriptional targeting strategy for treatment of glioma. J
Neurosurg 2006;104:583–92, doi:10.3171/jns.2006.104.4.583.
34. Webster A, Russell S, Talbot P, et al. Characterization of the
adenovirus proteinase: substrate specificity. J Gen Virol 1989;70(Pt
12):3225–34, doi:10.1099/0022-1317-70-12-3225.
35. Ghoshal K, Jacob ST. Regulation of metallothionein gene
expression. Prog Nucleic Acid Res Mol Biol 2001;66:357–84,
doi:10.1016/S0079-6603(00)66034-8.

11

36. Haq F, Mahoney M, Koropatnick J. Signaling events for
metallothionein induction. Mutat Res 2003;533:211–26, doi:10.
1016/j.mrfmmm.2003.07.014.
37. Vasak M. Advances in metallothionein structure and functions. J
Trace Elem Med Biol 2005;19:13–7, doi:10.1016/j.jtemb.2005.03.003.
38. Toriumi S, Saito T, Hosokawa T, et al. Metal binding ability of
metallothionein-3 expressed in Escherichia coli. Basic Clin Pharmacol
Toxicol 2005;96:295–301, doi:10.1111/j.1742-7843.2005.pto960404.x.
39. Nielson KB, Atkin CL, Winge DR. Distinct metal-binding
configurations in metallothionein. J Biol Chem 1985;260:5342–50.
40. Parker AL, Waddington SN, Nicol CG, et al. Multiple vitamin Kdependent coagulation zymogens promote adenovirus-mediated
gene delivery to hepatocytes. Blood 2006;108:2554–61, doi:10.1182/
blood-2006-04-008532.
41. Zaiss AK, Vilaysane A, Cotter MJ, et al. Antiviral antibodies target
adenovirus to phagolysosomes and amplify the innate immune
response. J Immunol 2009;182:7058–68, doi:10.4049/jimmunol.
0804269.
42. Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to
systemic adenoviral vectors in mice is mediated by dendritic cells
and macrophages. Mol Ther 2001;3:697–707, doi:10.1006/mthe.
2001.0329.
43. Rosa-Calatrava M, Grave L, Puvion-Dutilleul F, et al. Functional
analysis of adenovirus protein IX identifies domains involved in
capsid stability, transcriptional activity, and nuclear reorganization.
J Virol 2001;75:7131–41, doi:10.1128/JVI.75.15.7131-7141.2001.
44. Fabry CM, Rosa-Calatrava M, Moriscot C, et al. The C-terminal
domains of adenovirus serotype 5 protein IX assemble into an
antiparallel structure on the facets of the capsid. J Virol 2009;83:
1135–9, doi:10.1128/JVI.01808-08.
45. Xu Z, Tian J, Smith JS, Byrnes AP. Clearance of adenovirus
by Kupffer cells is mediated by scavenger receptors, natural
antibodies, and complement. J Virol 2008;82:11705–13, doi:10.
1128/JVI.01320-08.
46. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5
hexon mediates liver gene transfer. Cell 2008;132:397–409, doi:10.
1016/j.cell.2008.01.016.
47. Waddington SN, Parker AL, Havenga M, et al. Targeting of
adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo:
fundamental involvement of coagulation factors and redundancy
of CAR binding by Ad5. J Virol 2007;81:9568–71, doi:10.1128/
JVI.00663-07.
48. Cichon G, Boeckh-Herwig S, Schmidt HH, et al. Complement
activation by recombinant adenoviruses. Gene Ther 2001;8:1794–
800, doi:10.1038/sj.gt.3301611.
49. Jiang H, Wang Z, Serra D, et al. Recombinant adenovirus vectors
activate the alternative complement pathway, leading to the
binding of human complement protein C3 independent of antiAd antibodies. Mol Ther 2004;10:1140–2, doi:10.1016/j.ymthe.
2004.08.015.
50. Alba R, Bradshaw AC, Parker AL, et al. Identification of coagulation
factor (F)X binding sites on the adenovirus serotype 5 hexon: effect
of mutagenesis on FX interactions and gene transfer. Blood 2009;
114:965–71, doi:10.1182/blood-2009-03-208835.
51. Short JJ, Rivera AA, Wu H, et al. Substitution of adenovirus
serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces
factor X binding, decreases liver tropism, and improves antitumor
efficacy. Mol Cancer Ther 2010;9:2536–44, doi:10.1158/1535-7163.
MCT-10-0332.

12

Liu et al

52. Bradshaw AC, Coughlan L, Miller AM, et al. Biodistribution and
inflammatory profiles of novel penton and hexon double-mutant
serotype 5 adenoviruses. J Control Release 2012;164:394–402, doi:
10.1016/j.jconrel.2012.05.025.
53. Beatty MS, Curiel DT. Chapter two—Adenovirus strategies for
tissue-specific targeting. Adv Cancer Res 2012;115:39–67, doi:10.
1016/B978-0-12-398342-8.00002-1.
54. Bigott HM, Laforest R, Liu X, et al. Advances in the production,
processing and microPET image quality of technetium-94m. Nucl
Med Biol 2006;33:923–33, doi:10.1016/j.nucmedbio.2006.07.001.

55. Virzi F, Winnard P Jr, Fogarasi M, et al. Recombinant
metallothionein-conjugated streptavidin labeled with 188Re and
99mTc. Bioconjug Chem 1995;6:139–44, doi:10.1021/bc00031a018.
56. Orlova A, Tran TA, Ekblad T, et al. (186)Re-maSGS-Z
(HER2:342), a potential Affibody conjugate for systemic therapy
of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 2010;
37:260–9, doi:10.1007/s00259-009-1268-9.
57. Chang YJ, Yu CY, Hsu CW, et al. Molecular imaging and
therapeutic efficacy of 188Re-(DXR)-liposome-BBN in AR42J
pancreatic tumor-bearing mice. Oncol Rep 2012;28:1736–42.

